| Literature DB >> 33317466 |
Xuefeng Pan1, Benjie Wei2, Hong Wang1, Lingyu Ma1, Zhaoli Du2, Ying Chen3.
Abstract
BACKGROUND: Both genetic susceptibility and dysregulated lipid metabolism are important susceptibilities to preeclampsia. In the study, we devote to investigate the associations of FOXO3 and TLR7 genetic polymorphisms with preeclampsia in a Chinese population.Entities:
Keywords: BMI; Lipid metabolism; Preeclampsia; Single nucleotide polymorphism; rs2232365
Mesh:
Substances:
Year: 2020 PMID: 33317466 PMCID: PMC7737381 DOI: 10.1186/s12884-020-03479-6
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Fig. 1Flow chart showing the steps in participant analysis
Demographic and clinical features of the study subjects
| Variables | Controls( | PE ( | EOPE ( | LOPE ( | |||
|---|---|---|---|---|---|---|---|
| Maternal age ( years) | 30.00(28.00–33.00) | 31.00(28.00–35.00) | 33.00(28.00–37.00) | 30.00(27.00-33.50) | 0.078 | 0.001* | 0.935 |
| Gestation at delivery (weeks) | 39.43(38.86–39.86) | 35.43(32.57–37.57) | 31.86(29.86–33.14) | 37.00(35.93–38.43) | < 0.001 * | < 0.001 * | < 0.001 * |
| Height | 162.50(160.00-165.00) | 162.00(159.00-165.00) | 160.00 158.00-164.00) | 162.50(159.50–165.00) | 0.648 | 0.042 | 0.388 |
| Weight | 71.00 (66.00–80.00) | 76.00 (70.00–87.00) | 75.00(70.00-82.50) | 78.00(70.00-89.50) | < 0.001 * | 0.017 | < 0.001 * |
| BMI | 27.34(25.00-29.655) | 29.14(26.80–32.80) | 28.76(26.71–32.23) | 29.30(26.89–33.10) | < 0.001 * | 0.001* | < 0.001 * |
| TSH(Ulu/mL) | 2.06(1.51–2.89) | 3.69(2.29–5.19) | 3.66(2.21–4.87) | 3.69(2.35–5.31) | < 0.001 * | < 0.001 * | < 0.001 * |
| FT3 | 4.75(4.17–5.19) | 3.91(3.40–4.43) | 3.72(3.31–4.21) | 4.01(3.45–4.53) | < 0.001 * | < 0.001 * | < 0.001 * |
| FT4 | 10.94(9.84–13.13) | 11.82(10.37–13.45) | 11.32(10.37–13.45) | 12.02 (10.59–13.54) | 0.019* | 0.496 | 0.004* |
| TC (mmol/L) | 6.06 (5.36–6.95) | 6.03 (5.13–7.06) | 6.14 (5.27–7.48) | 5.98 (5.07-7.00) | 0.186 | 0.806 | 0.186 |
| TG (mmol/L) | 3.05 (2.46–3.96) | 3.51 (2.80–4.51) | 3.48 (2.65–4.43) | 3.57 (2.84–4.54) | 0.002 * | 0.026 | 0.002 * |
| HDL-C (mmol/L) | 1.86 (1.65–2.11) | 1.71 (1.44–2.05) | 1.76(1.49–2.11) | 1.68(1.39–1.98) | < 0.001 * | 0.128 | 0.001 * |
| LDL-C (mmol/L) | 2.87 (2.42–3.48) | 3.02 (2.52–3.72) | 3.10 (2.62–3.87) | 2.92 (2.40–3.70) | 0.460 | 0.052 | 0.532 |
| TG/HDL-C | 1.74 (1.32–2.24) | 2.14 (1.54–2.81) | 2.08 (1.52–2.65) | 2.19 (1.57–2.90) | < 0.001 * | 0.006* | < 0.001 * |
PE represents Preeclampsia, EOPE represents early- onset preeclampsia, LOPE represents late-onset preeclampsia, BMI Body mass index, TSH Thyroid-stimulating hormone, FT3 Free triiodothyronine, FT4 Free thyroxine, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein, LDL-C Low-density lipoprotein, TG/HDL Triglyceride/ high-density lipoprotein
All the continuous variables were presented as median and the 25th-75th percentile for non-normal distribution tested. P values were analysis using U-test
a PE vs. controls, b EOPE vs. controls, c LOPE vs. controls, Pa < 0.05; * Pb and PC < 0.017 for sub-group
Genotype and allele frequencies between study groups
| SNP ID | Model | Controls | PE | EOPE | LOPE | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNPs | ϰ2 | ϰ2 | ϰ2 | ||||||||
| rs2232365 | CC | 21(13.29%) | 35(19.77%) | 4.016 | 0.134 | 10(14.29%) | 0.799 | 0.671 | 25(23.36%) | 5.682 | 0.058 |
| CT | 80(50.63%) | 93(52.545) | 39(55.71%) | 54(50.47%) | |||||||
| TT | 57(36.08%) | 49(27.68%) | 21(30.00%) | 28(26.17%) | |||||||
| Genotype | TT+CT/CC | 137(86.71%) | 142(80.23%) | 2.520 | 0.112 | 60(85.71%) | 0.041 | 0.840 | 82(76.63%) | 4.513 | 0.034 |
| CC | 21(13.29) | 35(19.77%) | 10(14.29%) | 25(23.36%) | |||||||
| Allele | C | 122(38.61%) | 163(47.25%) | 0.052 | 59(42.14%) | 0.477 | 104(48.60%) | 0.021 | |||
| T | 194(61.39%) | 191(55.36%) | 81(57.86%) | 110(51.40%) | |||||||
| rs3853839 | CC | 10(6.33%) | 15(8.47%) | 3.731 | 0.155 | 7(10.00%) | 0.949 | 0.622 | 8(7.48%) | 6.490 | 0.039 |
| CG | 78(49.37%) | 69(38.98%) | 33(47.14%) | 36(33.64%) | |||||||
| GG | 70(44.30%) | 93(52.54%) | 30(42.86%) | 63(58.87%) | |||||||
| Genotype | CC+CG | 88(55.70%) | 84(47.46%) | 2.268 | 0.132 | 40(57.14%) | 0.041 | 0.839 | 44(41.12%) | 5.412 | 0.020 |
| GG | 70(44.30%) | 93(52.54%) | 30(42.86%) | 63(58.88%) | |||||||
| Allele | C | 98(31.01%) | 99(28.70%) | 0.747 | 47(33.57%) | 0.293 | 52(24.30%) | 0.092 | |||
| G | 218(68.99%) | 255(73.91%) | 93(66.43%) | 162(75.70%) | |||||||
| rs3761548 | GG | 88(55.70%) | 87(49.15%) | 1.489 | 0.475 | 33(47.14%) | 1.534 | 0.464 | 54(50.47%) | 0.713 | 0.700 |
| GT | 63(39.87%) | 82(46.33%) | 34(48.57%) | 48(44.86%) | |||||||
| TT | 7(4.43%) | 8(4.52%) | 3(4.29%) | 5(4.67%) | |||||||
| Genotype | TT+TG | 88(55.70%) | 87(49.15%) | 1.433 | 0.231 | 33(47.14%) | 1.425 | 0.233 | 54(50.47%) | 0.701 | 0.401 |
| GG | 70(44.30%) | 90(50.85%) | 37(52.86%) | 53(49.53%) | |||||||
| Allele | G | 239(75.63%) | 256(74.20%) | 0.329 | 100(71.43%) | 0.343 | 156()72.90% | 0.478 | |||
| T | 77(24.37%) | 98(28.41%) | 40(28.57%) | 58(27.11%) | |||||||
PE Represents Preeclampsia, EOPE Represents early- onset preeclampsia, LOPE Represents late-onset preeclampsia. a PE vs controls, b EOPE vs controls, c LOPE vs controls, * Pa < 0.05; * Pb and PC < 0.017 for sub-group
Association between genotype variants and clinical and biochemical parameters in LOPE groups
| SNP ID | Model (n) | BMI | TC | TG | HDL | LDL | TG/HDL | TSH | T3 | T4 |
|---|---|---|---|---|---|---|---|---|---|---|
| rs2232365(C/T) | TT + CT(82) | 29.01(26.63–34.05) | 5.80(5.06–7.06) | 3.72(2.81–4.66) | 1.61(1.33–1.95) | 2.91(2.36–3.72) | 2.35(1.64–3.23) | 3.29(2.31–5.42) | 4.05(3.49–4.48) | 12.14(10.59–14.24) |
| CC(25) | 29.88(28.26–31.96) | 6.21(5.22–6.75) | 3.30(2.89–3.99) | 1.77(1.63–2.10) | 2.97(2.46–3.58) | 1.88(1.52–2.32) | 4.44(3.18–5.19) | 3.93(3.45–4.58) | 12.00(10.74–12.64) | |
| 0.219 | 0.688 | 0.118 | 0.040* | 0.874 | 0.016* | 0.475 | 0.953 | 0.371 | ||
| rs3853839(C/G) | CC + CG(44) | 30.17(26.83–34.18) | 5.64(4.67–6.47) | 3.51(2.84–4.50) | 1.55(1.30–1.86) | 2.77(2.38–3.44) | 2.32(1.84–2.88) | 3.84(2.06–5.75) | 4.38(3.86–4.98) | 12.08(10.33–13.27) |
| GG(63) | 29.00(26.91–32.43) | 6.21(5.22–7.06) | 3.60(2.84–4.59) | 1.74(1.49–2.07) | 3.02(2.45–3.93) | 2.09(1.48–3.03) | 3.68(2.62–5.31) | 3.87(3.35–4.38) | 12.00(10.90-13.64) | |
| 0.296 | 0.141 | 0.648 | 0.063 | 0.222 | 0.425 | 0.894 | 0.005* | 0.423 | ||
| rs3761548(T/G) | GG + TG(102) | 29.10(26.76–32.77) | 5.96(5.06–7.02) | 3.57(2.81–4.51) | 1.67(1.38–1.97) | 2.95(2.39–3.77) | 2.18(1.53–2.92) | 3.70(2.39–5.43) | 4.02(3.45–4.52) | 12.08(10.58–13.54) |
| TT(5) | 34.29(29.24–35.20) | 6.57(5.46–6.75) | 3.60(3.35–4.96) | 1.78(1.62–2.13) | 2.77(2.70–3.10) | 2.72(1.94–2.79) | 3.65(1.96–4.74) | 3.98(3.87–4.58) | 12.00(11.86–12.02) | |
| 0.083 | 0.831 | 0.456 | 0.560 | 0.745 | 0.626 | 0.658 | 0.935 | 0.859 |
LOPE represents late-onset preeclampsia, BMI Body mass index, TSH Thyroid-stimulating hormone, FT3 Free triiodothyronine, FT4 Free thyroxine, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein, LDL-C Low-density lipoprotein, TG/HDL Triglyceride/ high-density lipoprotein. *P < 0.05 versus controls
Odds ratios (95% confidence intervals) for the association between PE and different parameters
| Sig. | Odds ratio | 95%CI for EXP (B) | ||
|---|---|---|---|---|
| Lower | Upper | |||
| PE | ||||
| BMI | <0.001※ | 1.199 | 1.116 | 1.289 |
| TG/HDL | <0.001※ | 1.747 | 1.283 | 2.379 |
| TSH(uIU) | <0.001※ | 1.982 | 1.621 | 2.432 |
| FT4 | 0.010※ | 1.109 | 1.025 | 1.200 |
| EOPE | ||||
| BMI | <0.001※ | 1.252 | 1.127 | 1.390 |
| TG/HDL | 0.014※ | 1.795 | 1.124 | 2.878 |
| TSH | <0.001※ | 1.967 | 1.506 | 2.569 |
| FT3 | <0.001※ | 0.283 | 0.177 | 0.450 |
| LOPE | ||||
| rs2232365(CC) | 0.004※ | 3.511 | 1.504 | 8.199 |
| BMI | <0.001※ | 1.248 | 1.142 | 1.363 |
| TSH(uIU) | <0.001※ | 2.113 | 1.646 | 2.712 |
| FT4 | 0.003※ | 1.223 | 1.070 | 1.396 |
| TG | 0.023※ | 0.578 | 0.360 | 0.925 |
| TG/HDL | <0.001※ | 4.087 | 1.938 | 8.618 |
※ P < 0.05 was considered statistically significant. PE represents preeclampsia, EOPE represents late-onset preeclampsia, LOPE represents late-onset preeclampsia, BMI Body mass index, TSH thyroid-stimulating hormone, FT3 Free triiodothyronine, FT4 Free thyroxine, TG Triglyceride, HDL High-density lipoprotein, TG/HDL Triglyceride/ high-density lipoprotein
Fig. 2The interactional associations of SNPs and biochemical parameters in LOPE. #The Continuous variable TG/HDL ratio was divided into two groups according to the median (1.843) of all TG/HDL for calculating extra risks